AEP30

Excess Glucocorticoid Activity May Suppress Tumor Immune Activity in Adrenocortical Carcinoma

Andrew E. Greenstein[1], Mouhammed Amir Habra[2], Marzena Mura[3], Paweł Biernat[3], Marek J. Piatek[3], Andreas Grauer[1], and Stacie Peacock Shepherd[4]

[1]Corcept Therapeutics, Menlo Park, CA, USA; [2]MD Anderson Cancer Center, Houston, TX, USA; [3]Ardigen SA, Krakow, Poland; [4]Formerly Corcept Therapeutics, Menlo Park, CA, USA

Contact: agreenstein@corcept.com

BACKGROUND

- Elevated glucocorticoid (GC) activity has been implicated in the pathophysiology of multiple cancer types, including breast, ovarian, squamous cell, and cervical cancer, as well as lymphomas.[1-5]
  - Patients administered GC prior to immune checkpoint inhibitor (ICI) therapy are reported to experience worse outcomes across multiple oncology indications.[6-8]
- Adrenocortical carcinoma (ACC), a rare endocrine cancer, is often accompanied by secretion of steroid hormones.
  - Approximately half of ACC tumors are functional, with 43% producing GC, either alone or in combination with other hormones.[9]
  - Therapies to reduce tumor burden for patients with ACC are limited and treatment outcomes are generally poor.
  - Presence of GC excess (GC+) is correlated with decreased overall survival and disease-free survival in patients with ACC.[9]
  - Furthermore, ACC patients with GC+ tumors show poor responses to ICI therapy.[10,11]
- We hypothesize that the broad immunosuppressive effects of GC may limit tumor immune response and ICI efficacy, which may be improved by glucocorticoid receptor (GR) antagonism.
- General hormone and GC abundance are annotated in The Cancer Genome Atlas (TCGA)[12] ACC dataset[13], which provides a unique test case to assess correlates of GC activity.

▶ Here, we present an ACC multi-omics analysis to identify the molecular consequences of GC activity and assess the rationale for combining relacorilant (CORT125134, Corcept Therapeutics), an investigational GR antagonist, with an ICI in the treatment of ACC with GC excess.

METHODS

- GC or other hormone excess (based on clinical signs and symptoms or biochemical evidence), mRNA expression, DNA mutation, and DNA methylation data from distinct adrenal resections (n=71) were accessed via the TCGA. Two sarcomatoid cases were excluded from the analysis.
- 394,036 methylation probes were analyzed and data were normalized using beta-mixture quantile normalization. Beta values represent the percentage of methylation in a gene.
- To deconvolute immune cell type abundance, xCell was applied to the mRNA data.[14]
- Tumor cases were scored using a published GR activity signature.[15]
- Random forests were used to derive a gene signature predictive of GC+ tumors.
  - Signature genes were identified by bootstrapping random forests on random subsets comprising 80% of the data and comparing the mean bootstrapped importance of genes with a threshold value.
  - The threshold value was calculated by applying the same procedure to a random forest predicting randomized labels instead of the true GC+/- labels to simulate lack of signal. The 99.9th quantile of gene importance (0.0028) was selected as the threshold.

RESULTS

CLASSIFYING ACC USING GC STATUS

- Using mRNA data in TCGA, genes that differed significantly by general hormone or GC status (>2-fold change and adjusted P≤.05) were identified.
- Presence or absence of GC excess (GC+/-) was identified as affecting the largest number of genes (858 genes, Comparison 1 in **Figure 1** and colored regions in **Figure 2**).
  - Presence vs absence of any hormone (H+/-) led to a significant difference in 439 genes (Comparison 2).
  - There was no significant difference between H- tumors and those expressing only non-GC hormones (NGC+, Comparison 3).
  - A comparison of NGC+ vs GC+ revealed 185 significantly different genes (Comparison 4).
- Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis identified higher gene expression in GC+ cases in several steroid-synthesis pathways and lower expression in a number of immune-related pathways (**Figure 3**).

Figure 1. Classification of TCGA ACC Tumors by Hormone Status.



Among the 4 comparisons performed, presence or absence of GC excess (GC+/-; Comparison 1) was associated with the largest number of significantly different genes in ACC.

Figures 2 & 3. Transcriptional Effects of GC Excess (A) and Overrepresented Downregulated and Upregulated KEGG Pathways in GC+ ACC Cases (B).



Figure 2 Expression of 858 genes was found to be significantly affected by GC excess. Genes with higher expression in GC+ cases (P≤.05 and >2-fold change in expression compared to GC-) are shown on the right (red). Those with lower expression in GC+ cases are shown on the left (blue). **Figure 3** Genes affected by GC excess include immune and steroid synthesis processes.

IMMUNE GENE SUPPRESSION IS ASSOCIATED WITH GC PRODUCTION

- Unsupervised clustering of normalized gene expression for the T-cell receptor signaling and natural-killer-cell-mediated cytotoxicity KEGG pathways showed lower gene expression in GC+ cases (**Figure 4**).
- When clustering GC+ and GC- separately, GC+ cases trended toward lower expression in these 2 immune-related pathways (**Figure 5**).

Figures 4 & 5. Unsupervised (4) and Supervised (5) Clustering of Normalized Gene Expression for 2 Immune KEGG Pathways.



Pathways shown include T-cell receptor signaling and natural-killer-cell-mediated cytotoxicity. The top 2 rows indicate GC and general hormone status for each tumor (black: GC+/H+, white: GC-/H-), shades of blue/red show normalized gene expression for each tumor, with darker blue corresponding to lower expression. **Figure 4** When clustering by gene expression, GC+ cases appear toward the right of the figure, where many genes show lower expression. **Figure 5** When clustering by GC status, in GC+ cases, lower gene expression dominates these pathways.

GC EXCESS IS ASSOCIATED WITH HYPO-METHYLATION OF STEROID SYNTHESIS GENES

- In GC+ ACC cases, a large number of genes were significantly hypomethylated (**Figure 6**, light blue), while fewer genes were hypermethylated (**Figure 6**, brown).
- Differences in methylation may explain the upregulation of steroidogenesis pathways but not the downregulation of immune pathways.
  - The hypomethylated genes were primarily associated with aldosterone, GC, and bile synthesis/secretion—pathways that are upregulated in GC+ ACC (**Figure 3**).
  - In contrast, the immune pathways with downregulated gene expression identified by mRNA analysis were not enriched in either the hypo- or hypermethylated sets.

Figure 6. Effects of GC on Promoter Methylation.



More genes were significantly hypo-methylated (P≤.05, Δ beta<-0.2) than hypermethylated (P≤.05, Δ beta>0.2) in GC+ tumors.

GC+ ACC TUMORS SHOW LOWER LYMPHOCYTE ABUNDANCE, HIGHER MYELOID AND MESENCHYMAL STEM CELL ABUNDANCE, AND HIGHER TUMOR MUTATION BURDEN

- Higher tumor mutation burden was also observed in the GC+ cases (*P*=.029, **Figure 7**).
- xCell analysis showed that T cells (*P*<.005) and natural killer T cells (NKT cells, *P*=.014) were less abundant in GC+ cases compared to GC- (**Figure 8**, top).
- In contrast, mesenchymal stem cells and neutrophils were more abundant in GC+ cases (*P*<.001, **Figure 8**, bottom).

Figure 7. Elevated Tumor Mutation Burden in GC+ ACC.



In GC+ cases, more missense and nonsense mutations were observed compared to GC-.

Figure 8. xCell Analysis of Cell Abundance in ACC Tumors.



Lymphocyte abundance was lower (top), while mesenchymal stem cell and neutrophil abundances were higher (bottom) in GC+ cases.

GR ACTIVITY IS HIGH IN ACC, INDEPENDENT OF HORMONE STATUS

- Tumor scoring using a published GR-driven gene signature[15] confirmed that GR activity is high in ACC compared to other tumor types in TCGA (**Figure 9**).
- There was no difference between ACC cases with different hormone and GC status (insert in **Figure 9**).

Figure 9. GR Activity Score for Different Tumor Types and ACC Subsets.



ACC exhibited high GR-driven gene activity relative to other tumors and independent of hormone status (see insert).

GENE SIGNATURE CAN PREDICT GC+ LIKE TUMOR CASES

- Random forest methods were used to derive a model that distinguishes GC+/- ACC cases with ROC AUC = 0.87 ± 0.09 (**Figure 10**).
  - The sensor component of the inflammasome (NLRP1) and a mediator of NK activation by IL-15 (ZNF683) were identified as important parts of this signature (insert in **Figure 10**).
- The gene signature was then applied to other tumor types in TCGA to identify those with GC+ like transcriptional profiles (**Figure 11**).
  - Based on the known distribution of GC+/- cases in ACC, a cutoff score of 0.75 was derived to distinguish GC+/- tumors (horizontal line in **Figure 11A**).
  - According to this score, uveal (UVM) and skin cutaneous melanomas (SKCM) may have the highest frequency of cases similar to GC+ ACC (**Figure 11B**).

Figure 10. Derivation of a Gene Signature that Distinguishes GC+/- ACC Cases Using Random Forest.



NLRP1 and ZNF683 (highlighted) were identified as important components of the signature. Only signature genes above the threshold of 0.0028 are shown.

Figure 11. Application of the ACC Gene Signature to TCGA Tumors (A) and Predicted Frequency of Tumor Cases Resembling GC+ ACC (B).



Uveal (UVM) and skin cutaneous melanomas (SKCM) are predicted to have the highest frequency of tumors that resemble GC+ ACC.

CONCLUSIONS

- Glucocorticoid excess affects significantly more genes in ACC than other hormones.
- In GC+ ACC, expression of steroid synthesis genes was elevated while immune-related genes were suppressed.
  - Normal adrenal cells express steroid synthesis genes but not immune-related genes.
  - Steroid synthesis genes were hypomethylated in GC+ cases, while no difference in methylation between GC+ and GC- cases was found for immune genes.
  - Furthermore, fewer infiltrating immune cells (T cells and NKT cells) were found in GC+ cases compared to GC-, suggesting that immune effects are due to changes in immune cell infiltrate rather than transcriptional changes.
- Tumor mutation burden was higher in GC+ ACC cases, which may be caused by the observed immune suppression or immune cell exclusion that may, in turn, be related to higher tolerance of non-self-antigens in GC+ cases.
- A published GR activity score showed no difference between GC+ and GC- cases, which may be due to locally high concentrations of GC in the adrenal gland regardless of systemic GC levels.
  - In contrast, immune infiltration into ACC tumors may be negatively affected by the exposure of lymph nodes to elevated GC activity.
- A newly derived gene signature predicts the highest frequency of GC+ like tumors in uveal and skin cutaneous melanomas.
- The observed reduced abundance of immune cells and immune-related transcripts in GC+ ACC provides insight into the mechanisms by which GC may limit response to ICI therapy.
  - GR antagonism may increase immune related transcripts or immune cell infiltration, thus promoting tumor immune response in GC+ ACC and other malignancies with elevated GC activity.
  - This hypothesis will be tested in a phase 1 oncology trial of relacorilant combined with ICI (CORT125134-551, NCT04373265).

REFERENCES

1. Abercrombie, H.C., et al. *Psychoneuroendocrinology*, 2004. 29(8): p. 1082-92.
2. Mormont, M.C. and F. Levi. *Int J Cancer*, 1997. 70(2): p. 241-7.
3. Sharma, P., et al. *J Oral Maxillofac Pathol*, 2018. 22(1): p. 27-34.
4. Palesh, O., et al. *J Clin Sleep Med*, 2008. 4(5): p. 441-9.
5. Jehn, C.F., et al. *Integr Cancer Ther*, 2010. 9(3): p. 270-5.
6. Arbour, K.C., et al. *J Clin Oncol*, 2018. 36(28): p. 2872-2878.
7. Scott, S.C. and N.A. Pennell. *J Thorac Oncol*, 2018. 13(11): p. 1771-1775.
8. Fuca, G., et al. *ESMO Open*, 2019. 4(1): p. e000457.
9. Else, T., et al. *J Clin Endocrinol Metab*, 2014. 99(2): p. 455-61.
10. Habra, M.A., et al. *J Immunother Cancer*, 2019. 7(1): p. 253.
11. Raj, N., et al. *J Clin Oncol*, 2020. 38(1): p. 71-80.
12. www.cancer.gov/tcga
13. Zheng, S., et al. *Cancer Cell*, 2016. 30(2): p. 363.
14. Aran, D., Z. Hu, and A.J. Butte. *Genome Biol*, 2017. 18(1): p. 220.
15. West, D.C., et al. *Clin Cancer Res*, 2018. 24(14): p. 3433-3446.

ACKNOWLEDGEMENTS

The results shown here are based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

Editorial support was provided by Tina K. Schlafly of Corcept Therapeutics. Funding for design and production support for this poster was provided by Corcept to MedVal Scientific Information Services, LLC (Princeton, NJ). The authors developed and revised the poster and provided approval of the final version.

DISCLOSURES

AEG and AG: Employee, Corcept; **SPS:** Former employee, Corcept; Stock ownership in Corcept, Abbot, and AbbVie; **MAH:** Consultant/Advisor, Corcept, HRA Pharma, and Calico; Investigator/Researcher for Exelixis, **MM, PB, MJP:** Employee, Ardigen

Presented at the 22nd European Congress of Endocrinology (e-ECE 2020), September 5–9, 2020